OncLive TV

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

William L. Dahut, MD, discusses the future of genetic screening in prostate cancer.

Warner K. Huh, MD, discusses some of the key challenges faced in the management of gynecologic cancers in light of the COVID-19 crisis, shares some of the resources provided by the SGO COVID-19 task force, and projects what is needed to quell the pandemic, which he refers to as version of the Great Depression.

Jean Wright, MD, discusses radiation considerations in breast cancer.

Ronald B. Natale, MD, discusses the evolution of immunotherapy in advanced non–small cell lung cancer.

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Ariela Noy, MD, discusses the next phase of a trial with devimistat in patients with relapsed/refractory Burkitt lymphoma.

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

Irene Ghobrial, MD, discusses the potential utility of triplet therapy in smoldering multiple myeloma.

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

William L. Dahut, MD, discusses the future of genetic screening in prostate cancer.

Karen E. Knudsen, PhD, discusses the rationale for investigating DNA-dependent protein kinase as a target in prostate cancer.

Warner K. Huh, MD, discusses some of the key challenges faced in the management of gynecologic cancers in light of the COVID-19 crisis, shares some of the resources provided by the SGO COVID-19 task force, and projects what is needed to quell the pandemic, which he refers to as version of the Great Depression.

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

John M. Pagel, MD, PhD, discusses the implications of the FDA approval of polatuzumab vedotin in diffuse large B-cell lymphoma.

Michael Wang, MD, discusses the evolution of treatment in mantle cell lymphoma.

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Hope S. Rugo, MD, discusses takeaways from the phase 3 IMpassion130 trial in metastatic triple-negative breast cancer.

Alanna K. Rahm, PhD, MS, discusses the challenges of implementing alternate delivery models for genetic counseling in prostate cancer.

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

Prithviraj Bose, MD, discusses novel agents under investigation in myelofibrosis.

Andrew Branagan, MD, discusses the results of the phase 3 TOURMALINE-MM3 trial in multiple myeloma.

John M. Pagel, MD, PhD, discusses the implications of the FDA approval of polatuzumab vedotin in diffuse large B-cell lymphoma.

Alanna K. Rahm, PhD, MS, discusses the challenges of implementing alternative delivery models for genetic counseling in prostate cancer.

Sonali M. Smith, MD, discusses frontline treatment options in mantle cell lymphoma.

Hope S. Rugo, MD, discusses takeaways from the phase 3 IMpassion130 trial in metastatic triple-negative breast cancer.

Lloyd B. Gayle, MD, discusses current treatment options for patients who develop breast implant–associated anaplastic large cell lymphoma (ALCL).

Jiaxin (Jason) Niu, MD, PhD, discusses combining immunotherapy with VEGF Inhibitors in extensive-stage small cell lung cancer.